EP0788351B1 - Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body - Google Patents
Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body Download PDFInfo
- Publication number
- EP0788351B1 EP0788351B1 EP95939752A EP95939752A EP0788351B1 EP 0788351 B1 EP0788351 B1 EP 0788351B1 EP 95939752 A EP95939752 A EP 95939752A EP 95939752 A EP95939752 A EP 95939752A EP 0788351 B1 EP0788351 B1 EP 0788351B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- reservoir
- rate
- drug
- bleomycin
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
Definitions
- the present invention relates to an implantable, refillable, rate-controlled drug delivery device, with a hollow reservoir, and a drug delivery tube communicating with the hollow reservoir.
- the drug delivery tube includes at least one rate-limiting permeable membrane which regulates drug delivery.
- a method of controlling the delivery of a drug to an internal portion of a body is also disclosed.
- U.S. Patent No. 3,310,051 to Schulte discloses a ventricular catheter with a reservoir, a backing member and a tube.
- U.S. Patent No. 5,511,355 to Franetzki et al. discloses an infusion device intended for implantation into the human body.
- the device comprises a flexible walled reservoir in a housing to contain the infusion liquid; a dosing unit for conveying the infusion liquid from the housing to a catheter, means permitting the refilling of the reservoir.
- the device is useful for delivering insulin.
- U.S. Patent No. 4,969,871 to Theeuwes et al. discloses a drug delivery device comprising a reservoir containing a beneficial agent to be delivered.
- the delivery device includes a drip chamber attached to tubing which is further attached to a transdermal delivery device.
- the tubing may have attached a formulator which includes a flow distributor.
- the delivery device is a transdermal drug delivery device comprising a reservoir attached to the skin by an adhesive.
- U.S. Patent No. 4,568,331 to Fischer et al. discloses a disposable medicine dispensing device.
- the device comprises a dispenser with walls which define a chamber which holds a medicament; a removable cap for refilling the reservoir; a delivery tube and a valve means for controlling delivery of the solution through the tube.
- Heyer Shulte Medical Catalog discloses an Ommaya reservoir with either an on-off flushing device, or with a pressure pump to regulate brain pressure.
- Codman Medical Catalog discloses an Ommaya reservoir with a pressure flow control.
- P.S. Medical Catalog discloses an Ommaya reservoir with a pressure flow control.
- Osmet by Alza is a pump which works by osmotic pressure, and polyanhydride matrices by Nova.
- Polyanhydrides are bioerodible polymers and this system uses matrices of drug (BCNU) in a polyanhydride base. The processes involved in release are dissolution of BCNU, diffusion through the matrix and breakdown of the polyanhydride. These systems work by a different mechanism to that reported here.
- U.S. Patent No. 5,087,616 to Meyers et al. discloses cytotoxic drug conjugates and their delivery to tumor cells.
- the cytotoxic substances include daunomycin, bleomycin, melphalan, chlorambucil, cysplatin, vinblastine, vincristine, or anti-metabolites such as methotrexate.
- U.S. Patent No. 5,051,257 to Pietronigro discloses anti-neoplastic solutions for direct intra-tumoral delivery.
- the anti-neoplastic agents include nitrosourea, preferably BCNU. (1,3-bis(2-chloroethyl)-1-nitrosourea).
- the compound may be needle injected into brain tumors.
- U.S. Patent No. 4,273,761 to Matsuda et al. discloses an anti-tumor composition containing bleomycin and an absorption enhancer for the treatment of a gastrointestinal tumor site.
- the drug is administered orally or through subcutaneous injection.
- U.S. Patent No. 5,229,500 to Barde et al. discloses a brain derived neurotrophic factor (or BDNF) which can be delivered via an Ommaya reservoir (see column 35, lines 33-35).
- BDNF brain derived neurotrophic factor
- U.S. Patent No. 5,180,820 to Barde et al. discloses antibodies directed toward brain derived neurotrophic factor-which can be delivered via an Ommaya reservoir.
- Known devices may include pressure releasing valves to release or regulate pressure in the brain or drain fluid from the brain.
- No rate-limiting permeable membrane designed to release the drug to be delivered at a controlled rate or means for controlling drug delivery is present in existing implantable drug delivery devices.
- the present device overcomes the deficiencies of the prior art by providing an implantable, refillable, drug delivery device with a means for controlling drug delivery with at least one rate-limiting permeable membrane.
- the delivery tube is equipped with at least one rate-limiting permeable membrane designed to release the drug to be delivered at a controlled rate.
- the device is adapted to deliver a drug to a brain tumor at a controlled rate.
- This invention provides a device which, once implanted, gives continuous access to internal regions of the body without requiring additional needle penetrations into these regions. Instead, a tubular portion of the device remains in the body and extends to the affected area where it serves as a continuously-available conduit placed there but once. Thereafter, a syringe or other device need only be placed in fluid communication with this conduit to inject, withdraw or mix fluids in the interior reservoir.
- the device has a rate-limiting permeable membrane designed to release the drug to be delivered at a controlled rate.
- the device further comprises a backing member, such as a membrane, circumscribing the hollow reservoir.
- the device is designed to deliver a drug to a brain tumor at a controlled rate.
- the apparatus of the invention is composed of a refill-able reservoir containing a drug solution connected to a delivery tube.
- the tube is inserted into the target region of the brain (tumor) through a hole drilled in the skull.
- the reservoir remains outside the skull under the scalp so it can be easily refilled. Diffusion of drug from the reservoir into the tube and hence the brain is controlled by a rate-limiting permeable membrane.
- the rate of delivery into the brain is controlled by the membrane and by the drug concentration in the reservoir.
- This device enables a large variety of drugs and other agents to be delivered into any internal region of the body, preferably the brain.
- Bleomycin is a preferred drug used in the reservoir delivery device for the treatment of brain tumors.
- Brain tumors are the second leading cause of death from cancer in pediatrics and the fourth leading cause among middle aged men.
- Each year in the United States approximately 40,000 people are diagnosed with a primary brain tumor or secondary brain malignancy (1) [see References below] and 10,000 die (2).
- Glioblastoma is particularly devastating.
- the 2 year survival rate is approximately 25% (3) and new treatment modalities are urgently needed.
- IT direct intratumoral
- An advantage of this route is that most primary brain tumors and metastases are localized in a single region so IT injection can localize, at least initially, delivery to the target area.
- Human and animal studies with IT delivery of antibiotics such as adriamycin (6) and lomustine, (7) have demonstrated high concentrations of drug in the brain and, in some cases, increased survival times (6).
- Bleomycins are a group of large (molecular weight 1400) hydrophilic compounds isolated from streptomyces verticillus. Bleomycins are believed to interact with DNA and cause strand scission, a review of the mode of action is given by Byrnes et al., 1990 (11). Bleomycin causes an accumulation of cells in the G2 phase in vitro (12) and are used in a variety of tumors including squamous carcinomas of the skin, neck and lungs in addition to lymphomas and testicular tumors (12). Bleomycin localizes on and within tumor cells (13) and has a special affinity for ectodermal tissues (14).
- Bleomycin has been shown to inhibit the growth of human glioma cells in culture at a concentration of over 0.47 ⁇ M (15). As gliomas are ectodermal in origin, bleomycin could be expected to be effective against these tumors. Bleomycin is preferentially taken up by malignant brain tissue and 57 Co labelled bleomycin scintigraphy can be used to detect brain metastases (16).
- Polyvinyl alcohol 98% hydrolyzed, was purchased from Aldrich Chemical Co. The molecular weight range was 70 - 80k.
- Bleomycin sulphate (Blenoxane) was obtained from Nippon Kayaku Co. Ltd. of Japan.
- Sodium phosphate (mono and di basic was purchased from Fisher Scientific) .
- PVA polyvinyl alcohol
- solutions of polyvinyl alcohol were prepared by dissolving 2 g of PVA in 100 ml of deionized water at 80°C. After cooling to room temperature the solution was poured onto a glass plate and allowed to dry forming a thin film. The film was then removed and heated to 120°C for 2 hours. 1 cm 2 pieces of the film were cut and fixed (figure 1). The hollow reservoirs were filled with phosphate buffer (pH 7.4) containing 3 U/mL bleomycin and the delivery tubes immersed in 5 mL buffer. Care was taken to ensure that no air bubbles were trapped in the reservoir, tube or connector. Samples (1 mL) were periodically removed and assayed by uv detection at 290 nm.
- the bleomycin solution was removed from the reservoir with a 5 ml syringe and a 20 gauge needle. The reservoir was then refilled with a 10 U/mL bleomycin solution and the release again measured for 10 days. The same process was repeated once more with a 22.5 U/ml bleomycin solution.
- Animals were anesthetized by subcutaneous injection of 0.4 ml of a ketamine/rompun mixture (55%:45%). The skull was then exposed with a #11 scalpel and a 3 mm hole drilled through the skull to expose the dura. The tip of the tube was then inserted through the dura to a depth of 3 mm. The tube was then fixed in place with dental acrylic and the wound closed with silk suture. The reservoir was then filled with a 3 U/ml bleomycin solution. An incision was then made in the rat's back and the reservoir implanted under the skin.
- a device comprises a tube having a central passage, the tube being adapted to be inserted in to an internal portion of the body so that its passage communicates with a selected region therein.
- a hollow reservoir is adapted to be connected to this tube and to be placed beneath the skin of the body.
- This hollow reservoir comprises an enclosure which has an internal periphery and a first and second wall, these walls facing each other inside the reservoir. The wall next to the skin is tolerant to, and self-sealing after, needle puncture.
- One of the walls has a passage through the tube.
- the tube is adapted to include a rate-limiting permeable membrane to control the rate of drug delivery to the target area. In a preferred embodiment the delivery tube comprises two rate-limiting permeable membranes.
- the invention relates to an implantable, refillable reservoir containing a drug solution connected to a delivery tube.
- the tube is inserted into an internal target region of the body. Diffusion of the drug from the reservoir into the tube and into the target area of the body is controlled by a rate-limiting permeable membrane. The rate of delivery into the target area of the body is controlled by the membrane and by the drug concentration in the reservoir.
- one of the walls is flexible and palpable through the skin by force exerted by the hand.
- the material of the flexible wall is flexible enough to be moved toward the other wall and thereby reduce the volume of the reservoir, and also sufficiently springy to return to its normal unstressed condition, thereby providing for pumping means to create bi-directional flow in the passages for mixing purposes.
- FIG. 4 illustrates a skull 10, showing the scalp 11 and the bone 12 of the skull surrounding the brain 13.
- the drawing of the anatomical portions is simplified because these form no portion of the present invention.
- the device is installed within a burr hole 14 having an internal wall 15 in the bone of the skull, and is held beneath the skin of the scalp by means of a sutured slit 16.
- the reservoir, elements 20 comprising the invention includes a tube 21 having a central passage 22 and a closed end 23. Perforations 24 through the wall provide for fluid communication between the passage and the outside of the tube.
- the tube is connected to a reservoir 25 by means of a connector 26, which connector is attached to a passage extension 27 which has a passage 28 that enters the reservoir itself through one wall thereof.
- the tube is equipped with at least one rate-limiting permeable membrane 38 for controlling the rate of drug delivery to the target area of drug delivery. In an alternative embodiment the rate-limiting permeable membrane may be placed in any location in the tube or between the opening of the reservoir and the tube.
- the reservoir has a boss 29 which fits within burr hole 14 and provides for lateral restraint of the device. The reservoir outward of the boss rests on the skull so as to give longitudinal restraint.
- the reservoir is a continuous enclosure and includes a circumferential periphery defined by circumferential edge 30.
- First and second interior walls 31, 32 are provided on opposite sides of the periphery.
- the first wall lies closer to the skull, and includes an interior crown 33 which surrounds the opening 34 of passage 28 into the interior of the reservoir.
- the crown has a plurality of notches 35 formed therein.
- Second wall 32 is generally domed and has a central section which is thicker than the edges. This wall is flexible and, as best shown in FIG. 4, is adapted to be palpated by finger pressure through the scalp to move it toward the first wall, thereby reducing the volume of the reservoir.
- the crown is provided to hold them apart. However, the notches provide for fluid flow past the crown to the passage even when the second wall is pressed against the crown.
- the entire structure is made of material which is compatible with the human tissue with which it comes in contact.
- a convenient substance is silicone rubber manufactured by Dow Corning Company, of Midland, Michigan.
- the material of the device is polyvinyl alcohol.
- the backing member may be composed of any material tolerated by the human body, preferably ethylene vinyl acetate, Teflon, silicone, silastic and nylon.
- the rate-limiting permeable membrane may be composed of a composition such as polyvinyl alcohol, ethylene vinyl acetate, silicone, nylon, polypropylene, polcarbonate, cellulose, cellulose acetate, cellulose esters or polyether sulfone.
- the thickness of the second wall is selected such that it is springy enough to restore itself to its normal, unstressed condition shown in FIG. 4, and yet sufficiently flexible that it can be deflected to the configuration shown in FIG. 7. It is also tolerant to repetitive needle punctures (with a reasonable number), because, as best shown in FIG. 4, material may be injected from a hypodermic syringe 36 by puncturing the scalp and the second wall with the needle. When the needle is withdrawn, the material of the second wall will seal the opening made by the needle.
- the device may be used to control the rate of drug delivery to any internal region of the body.
- the device is adapted for only drug delivery.
- the tube will be forced into this region by means well known in the surgical arts. Once in place, this tube is connected to the reservoir, and the reservoir is placed in position as shown, and the scalp sutured over the reservoir. Medication may be introduced to the region by a syringe as shown, mixing being attained either by depressing the second wall or by pumping with the syringe.
- this device provides a reservoir of fluid which in effect is an extension of a region under treatment or study. Only one puncture of the brain or other region is necessary because the tube remains in place for sensible periods of time to provide a continuously-available conduit to the region, and the dome is available for introduction and withdrawal, of material even were the second wall to be too stiff to flex. On the other hand, should the device be made flexible enough for this purpose, then even better results may be attained as a result of the more complete bi-directional flow attainable thereby.
- a phase I trial of IT bleomycin for recurrent malignant gliomas was completed using the implantable reservoir according to the present invention. See University of Kentucky IRB #93-30026. The device was extremely well tolerated.
- Nine patients were enrolled in a dose escalation study and received weekly doses of bleomycin beginning at 4.9 units per week and escalating to 24.5 units per week.
- the study determined that the maximum tolerable weekly doses of intratumoral bleomycin is 16 units per week.
- Toxicity, when present, was minimal at even higher doses and, when present, consisted of drowsiness, lethargy and increased seizure frequency in those patients with existing seizure disorders.
- Two patients who received cumulative doses of 300 units developed skin ulcers around the injection sites.
- the invention provides an implantable, refillable reservoir containing a drug solution connected to a delivery tube.
- the tube is inserted into a specific target region of the body or may be placed in a region such as a blood vessel, to provide systemic distribution of the drug.
- Diffusion of the drug from the reservoir into the tube and into the target area of the body is controlled by at least one rate-limiting permeable membrane.
- the rate of delivery into the target area of the body is controlled by the membrane and by the drug concentration in the reservoir.
Abstract
Description
Claims (10)
- An implantable, refillable, rate-controlled drug delivery device, comprising a hollow reservoir and a drug delivery tube communicating with the hollow reservoir, wherein said device comprises at least one rate-limiting permeable membrane which membrane regulates drug delivery.
- The device according to claim 1, wherein at least one rate-limiting permeable membrane is located within the drug delivery tube.
- The device according to claim 1, wherein at least one rate-limiting permeable membrane is located between the opening of the hollow reservoir and the drug delivery tube.
- The device according to claim 1, wherein said device comprises two rate-limiting permeable membranes.
- The device according to claim 1, wherein said hollow reservoir contains a drug to be delivered at a controlled rate to an internal target area of the body.
- The device according to claim 5, wherein said internal target area of the body is the brain.
- The device according to claim 1, further comprising a backing member circumscribing the hollow reservoir.
- The device according to claim 7, wherein said backing member is a membrane.
- The device according to claim 1, for controlling the delivery of an anti-tumor drug to an internal portion of a body.
- The device according to claim 1, for administering an anti-tumor drug to a brain tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US339246 | 1989-04-17 | ||
US33924694A | 1994-11-10 | 1994-11-10 | |
PCT/US1995/014319 WO1996014834A1 (en) | 1994-11-10 | 1995-11-09 | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0788351A1 EP0788351A1 (en) | 1997-08-13 |
EP0788351A4 EP0788351A4 (en) | 1998-03-11 |
EP0788351B1 true EP0788351B1 (en) | 2003-02-05 |
Family
ID=23328150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95939752A Expired - Lifetime EP0788351B1 (en) | 1994-11-10 | 1995-11-09 | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
Country Status (11)
Country | Link |
---|---|
US (1) | US5836935A (en) |
EP (1) | EP0788351B1 (en) |
JP (1) | JP3251294B2 (en) |
AT (1) | ATE232089T1 (en) |
AU (1) | AU708529B2 (en) |
CA (1) | CA2204789C (en) |
DE (1) | DE69529572T2 (en) |
DK (1) | DK0788351T3 (en) |
ES (1) | ES2191719T3 (en) |
PT (1) | PT788351E (en) |
WO (1) | WO1996014834A1 (en) |
Families Citing this family (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117643A (en) * | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
US6485514B1 (en) | 1997-12-12 | 2002-11-26 | Supergen, Inc. | Local delivery of therapeutic agents |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
EP1137451A4 (en) * | 1998-12-07 | 2003-05-21 | Std Mfg Inc | Implantable vascular access device |
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
US20010041870A1 (en) * | 1999-03-09 | 2001-11-15 | Edward M. Gillis | Implantable device for access to a treatment site |
US6554822B1 (en) | 1999-04-30 | 2003-04-29 | University Of Southern California | Microbolus infusion pump |
US6139535A (en) * | 1999-05-27 | 2000-10-31 | Situs Corporation | Method and apparatus for placement and activation of a medical device within a body cavity |
US6471635B1 (en) | 2000-02-10 | 2002-10-29 | Obtech Medical Ag | Anal incontinence disease treatment with controlled wireless energy supply |
US6464628B1 (en) | 1999-08-12 | 2002-10-15 | Obtech Medical Ag | Mechanical anal incontinence |
US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
US6361522B1 (en) | 1999-10-21 | 2002-03-26 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable cardiac device |
ATE283013T1 (en) | 1999-10-21 | 2004-12-15 | Alcon Inc | MEDICATION DELIVERY DEVICE |
US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
CA2383572C (en) | 1999-10-21 | 2007-12-11 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
CN1698552B (en) | 2000-02-10 | 2010-05-12 | 厄罗洛吉卡股份公司 | Controlled urinary incontinence treatment |
ATE295136T1 (en) | 2000-02-10 | 2005-05-15 | Potencia Medical Ag | MECHANICAL DEVICE FOR TREATING IMPOTENCY |
ATE296071T1 (en) | 2000-02-14 | 2005-06-15 | Potencia Medical Ag | PENIS PROSTHESIS |
US20090209831A1 (en) * | 2000-06-28 | 2009-08-20 | Nexgen Medical Systems, Incorporated | Imaging methods for visualizing implanted living cells |
US6409698B1 (en) | 2000-11-27 | 2002-06-25 | John N. Robinson | Perforate electrodiffusion pump |
KR20030005167A (en) * | 2000-11-30 | 2003-01-17 | 다이셀 가가꾸 고교 가부시끼가이샤 | Transfer Sheet |
CA2431688A1 (en) * | 2000-12-14 | 2002-09-26 | David A. Watson | Implantable refillable and rate controlled drug delivery device |
US6689117B2 (en) | 2000-12-18 | 2004-02-10 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable medical device |
DE10105592A1 (en) | 2001-02-06 | 2002-08-08 | Achim Goepferich | Placeholder for drug release in the frontal sinus |
US6726678B1 (en) * | 2001-02-22 | 2004-04-27 | Isurgical, Llc | Implantable reservoir and system for delivery of a therapeutic agent |
US6997914B2 (en) * | 2001-04-02 | 2006-02-14 | Horizon Medical Products, Inc. | Implantable access port |
JP2004536631A (en) | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Implantable drug delivery device and use thereof |
EP1404297B1 (en) | 2001-06-12 | 2011-04-27 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US7209783B2 (en) * | 2001-06-15 | 2007-04-24 | Cardiac Pacemakers, Inc. | Ablation stent for treating atrial fibrillation |
US7493162B2 (en) | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
AU2002319606B2 (en) * | 2001-07-23 | 2006-09-14 | Alcon, Inc. | Ophthalmic drug delivery device |
EP1409065B1 (en) | 2001-07-23 | 2007-01-17 | Alcon, Inc. | Ophthalmic drug delivery device |
US7749528B2 (en) * | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
RU2311892C2 (en) * | 2001-08-29 | 2007-12-10 | КАРВАЛХО Рикардо А. П. ДЕ | Implantable sealable system for one-way delivery of therapeutic preparations to tissues |
US7340303B2 (en) | 2001-09-25 | 2008-03-04 | Cardiac Pacemakers, Inc. | Evoked response sensing for ischemia detection |
US6758828B2 (en) | 2001-12-10 | 2004-07-06 | Regents Of The University Of Minnesota | Catheter for cell delivery in tissue |
US20050107753A1 (en) * | 2002-02-01 | 2005-05-19 | Ali Rezai | Microinfusion device |
AU2003215164A1 (en) * | 2002-02-13 | 2003-09-04 | Kuchta, John | Controlled cerebrospinal infusion and shunt system |
US7236821B2 (en) * | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
US20030229333A1 (en) * | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
MXPA04008903A (en) * | 2002-03-11 | 2004-11-26 | Alcon Inc | Implantable drug delivery system. |
US20030176797A1 (en) * | 2002-03-12 | 2003-09-18 | Fernando Anzellini | Thrombust; implantable delivery system sensible to self diagnosis of acute myocardial infarction for thrombolysis in the first minutes of chest pain |
US8926573B2 (en) * | 2002-04-02 | 2015-01-06 | Angiodynamics, Inc. | Implantable access port |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US6978174B2 (en) * | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
GB2389791B (en) * | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
US6568177B1 (en) * | 2002-06-04 | 2003-05-27 | Ford Global Technologies, Llc | Method for rapid catalyst heating |
US7089055B2 (en) | 2002-06-28 | 2006-08-08 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering pre-shock defibrillation therapy |
US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
CN100355455C (en) * | 2002-07-15 | 2007-12-19 | 爱尔康公司 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
US20040064110A1 (en) * | 2002-10-01 | 2004-04-01 | Peter Forsell | Injection port |
US7615070B2 (en) * | 2002-10-11 | 2009-11-10 | Spineco, Inc. | Electro-stimulation and medical delivery device |
US20040073221A1 (en) | 2002-10-11 | 2004-04-15 | Spineco, Inc., A Corporation Of Ohio | Electro-stimulation and medical delivery device |
US8574204B2 (en) | 2002-10-21 | 2013-11-05 | Angiodynamics, Inc. | Implantable medical device for improved placement and adherence in the body |
US6657038B1 (en) | 2002-11-01 | 2003-12-02 | General Electric Company | Method for making copolycarbonates |
US7072711B2 (en) | 2002-11-12 | 2006-07-04 | Cardiac Pacemakers, Inc. | Implantable device for delivering cardiac drug therapy |
US7596408B2 (en) | 2002-12-09 | 2009-09-29 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
WO2004052452A1 (en) | 2002-12-09 | 2004-06-24 | Medtronic, Inc. | Reducing relative intermodule motion in a modular implantable medical device |
JP2006512370A (en) * | 2002-12-19 | 2006-04-13 | アルザ・コーポレーション | A stable non-aqueous single phase gel and its formulation for delivery from an implantable device |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US9445901B2 (en) * | 2003-03-12 | 2016-09-20 | Deger C. Tunc | Prosthesis with sustained release analgesic |
AR043809A1 (en) | 2003-03-31 | 2005-08-17 | Alza Corp | OSMOTIC PUMP WITH MEDIUM TO DISSIP INTERNAL PRESSURE |
KR20050120767A (en) * | 2003-03-31 | 2005-12-23 | 알자 코포레이션 | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
RU2005133427A (en) * | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | WATERLESS SINGLE-PHASE CARRIERS AND DRUGS USING SUCH CARRIERS |
US7317947B2 (en) | 2003-05-16 | 2008-01-08 | Medtronic, Inc. | Headset recharger for cranially implantable medical devices |
US7263401B2 (en) | 2003-05-16 | 2007-08-28 | Medtronic, Inc. | Implantable medical device with a nonhermetic battery |
ZA200508654B (en) * | 2003-07-10 | 2007-01-31 | Alcon Inc | Ophthalmic drug delivery device |
US7320675B2 (en) | 2003-08-21 | 2008-01-22 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US8070785B2 (en) | 2003-09-16 | 2011-12-06 | Spineco, Inc. | Bone anchor prosthesis and system |
CN1859900A (en) | 2003-09-30 | 2006-11-08 | 阿尔萨公司 | Osmotically driven active agent delivery device providing an ascending release profile |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7347854B2 (en) * | 2004-03-02 | 2008-03-25 | Infusion Systems, Llc | Method and apparatus for automatically modifying delivery profile of drug delivery system |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US7720521B2 (en) | 2004-04-21 | 2010-05-18 | Acclarent, Inc. | Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
US7410480B2 (en) | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US8146400B2 (en) | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7596399B2 (en) | 2004-04-29 | 2009-09-29 | Medtronic, Inc | Implantation of implantable medical device |
US20050245984A1 (en) | 2004-04-30 | 2005-11-03 | Medtronic, Inc. | Implantable medical device with lubricious material |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7811266B2 (en) * | 2004-07-13 | 2010-10-12 | Std Med, Inc. | Volume reducing reservoir insert for an infusion port |
FR2873016B1 (en) * | 2004-07-15 | 2006-09-29 | Pierre Marcel Bourgogne | ARTIFICIAL VASCULAR PROSTHESES THAT PERMANENTLY DELIVER ACTIVE PRODUCTS WHICH PREVENT ALL STENOSIS, THROMBOSIS, CELL PROLIFERATION, ETC .. PERMANENT EASY ACCESS FOR ANY INTERVENTION |
EP2583717B1 (en) | 2004-07-28 | 2019-02-20 | Medtronic Ardian Luxembourg S.à.r.l. | Methods and devices for renal nerve blocking |
US8246569B1 (en) | 2004-08-17 | 2012-08-21 | California Institute Of Technology | Implantable intraocular pressure drain |
US7567841B2 (en) | 2004-08-20 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering combined electrical and drug therapies |
EP1799134A4 (en) * | 2004-09-14 | 2011-03-09 | Spineco Inc | Implant device |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8874204B2 (en) | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
EP1846080A4 (en) * | 2005-01-19 | 2010-05-19 | Sentinel Group Llc | Medical agent delivery system and method |
EP1861161A4 (en) * | 2005-01-24 | 2012-05-16 | Neurosystec Corp | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
EP1858565B1 (en) | 2005-03-04 | 2021-08-11 | C.R. Bard, Inc. | Access port identification systems and methods |
US20110077579A1 (en) * | 2005-03-24 | 2011-03-31 | Harrison William V | Cochlear implant with localized fluid transport |
US8147455B2 (en) | 2005-04-27 | 2012-04-03 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
EP3884989B1 (en) | 2005-04-27 | 2022-07-13 | C. R. Bard, Inc. | Vascular access port |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
US20060258994A1 (en) * | 2005-05-12 | 2006-11-16 | Avery Robert L | Implantable delivery device for administering pharmacological agents to an internal portion of a body |
US20060280655A1 (en) * | 2005-06-08 | 2006-12-14 | California Institute Of Technology | Intravascular diagnostic and therapeutic sampling device |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US20070073250A1 (en) * | 2005-07-08 | 2007-03-29 | Schneiter James A | Implantable port |
US20070027105A1 (en) * | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
CN101600475A (en) | 2005-07-27 | 2009-12-09 | 佛罗里达大学研究基金会有限公司 | Revise the miniaturization compound and the use thereof of protein false folding |
US8114113B2 (en) | 2005-09-23 | 2012-02-14 | Acclarent, Inc. | Multi-conduit balloon catheter |
US7790671B2 (en) * | 2005-10-07 | 2010-09-07 | Codman & Shurtleff, Inc. | Implantable pump for protein delivery for obesity control by drug infusion into the brain |
US7616990B2 (en) | 2005-10-24 | 2009-11-10 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
MX2008006379A (en) | 2005-11-29 | 2009-03-03 | Smithkline Beecham Corp | Treatment method. |
EP1998829B1 (en) | 2006-03-14 | 2011-02-09 | University Of Southern California | Mems device for delivery of therapeutic agents |
US9084901B2 (en) | 2006-04-28 | 2015-07-21 | Medtronic, Inc. | Cranial implant |
US8267905B2 (en) | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
US8190389B2 (en) | 2006-05-17 | 2012-05-29 | Acclarent, Inc. | Adapter for attaching electromagnetic image guidance components to a medical device |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
CA2657380A1 (en) * | 2006-07-20 | 2008-01-24 | Neurosystec Corporation | Devices, systems and methods for ophthalmic drug delivery |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
GB0623395D0 (en) | 2006-11-23 | 2007-01-03 | Renishaw Plc | Port |
US8439687B1 (en) | 2006-12-29 | 2013-05-14 | Acclarent, Inc. | Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices |
US7844345B2 (en) * | 2007-02-08 | 2010-11-30 | Neuropace, Inc. | Drug eluting lead systems |
US7813811B2 (en) * | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
WO2008124787A2 (en) | 2007-04-09 | 2008-10-16 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8118757B2 (en) | 2007-04-30 | 2012-02-21 | Acclarent, Inc. | Methods and devices for ostium measurement |
US8485199B2 (en) | 2007-05-08 | 2013-07-16 | Acclarent, Inc. | Methods and devices for protecting nasal turbinate during surgery |
CA2687330A1 (en) | 2007-05-18 | 2008-11-27 | The Johns Hopkins University | A treatment simulator for brain diseases and method of use thereof |
EP3269417A1 (en) | 2007-06-20 | 2018-01-17 | Medical Components, Inc. | Implantable access port with molded and/or radiopaque indicia |
US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
ES2650800T3 (en) | 2007-07-19 | 2018-01-22 | Medical Components, Inc. | Venous reservoir set with X-ray discernible indications |
EP2217320A2 (en) * | 2007-10-05 | 2010-08-18 | AngioDynamics, Inc. | Dual reservoir implantable access port |
SI2211768T1 (en) | 2007-10-11 | 2021-11-30 | Implantica Patent Ltd. | Apparatus for controlling flow in a bodily organ |
US8696543B2 (en) | 2007-10-11 | 2014-04-15 | Kirk Promotion Ltd. | Method for controlling flow of intestinal contents in a patient's intestines |
US8992409B2 (en) | 2007-10-11 | 2015-03-31 | Peter Forsell | Method for controlling flow in a bodily organ |
WO2010042045A1 (en) | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | A system, an apparatus, and a method for treating a sexual dysfunctional female patient |
US8795153B2 (en) | 2007-10-11 | 2014-08-05 | Peter Forsell | Method for treating female sexual dysfunction |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
EP2666510B1 (en) | 2007-12-20 | 2017-10-18 | University Of Southern California | Apparatus for controlled delivery of therapeutic agents |
US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US20090192493A1 (en) * | 2008-01-03 | 2009-07-30 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
WO2009092067A2 (en) * | 2008-01-18 | 2009-07-23 | Neurosystec Corporation | Valveless impedance pump drug delivery systems |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US8182432B2 (en) | 2008-03-10 | 2012-05-22 | Acclarent, Inc. | Corewire design and construction for medical devices |
CN104353150A (en) * | 2008-05-08 | 2015-02-18 | 迷你泵有限责任公司 | Implantable pums and cannulas therefor |
CN103394142B (en) | 2008-05-08 | 2015-08-19 | 迷你泵有限责任公司 | Implantable drug delivery devices with for filling equipment and the method for this device |
US8231609B2 (en) * | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
MX2011001099A (en) | 2008-07-30 | 2011-03-15 | Acclarent Inc | Paranasal ostium finder devices and methods. |
JP5584687B2 (en) | 2008-09-18 | 2014-09-03 | アクラレント インコーポレイテッド | Method and apparatus for treating ear, nose and throat disorders |
US8600510B2 (en) | 2008-10-10 | 2013-12-03 | Milux Holding Sa | Apparatus, system and operation method for the treatment of female sexual dysfunction |
CN102271737B (en) | 2008-10-31 | 2016-02-17 | C·R·巴德股份有限公司 | For providing the subcutaneous entry port entered of patient |
US9393432B2 (en) | 2008-10-31 | 2016-07-19 | Medtronic, Inc. | Non-hermetic direct current interconnect |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (en) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US20100241155A1 (en) | 2009-03-20 | 2010-09-23 | Acclarent, Inc. | Guide system with suction |
US8435290B2 (en) | 2009-03-31 | 2013-05-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US7978742B1 (en) | 2010-03-24 | 2011-07-12 | Corning Incorporated | Methods for operating diode lasers |
US8372036B2 (en) | 2009-05-06 | 2013-02-12 | Alcon Research, Ltd. | Multi-layer heat assembly for a drug delivery device |
IN2012DN00352A (en) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
WO2011005847A1 (en) | 2009-07-07 | 2011-01-13 | C. R. Bard, Inc. | Extensible internal bolster for a medical device |
EP2467797B1 (en) * | 2009-08-18 | 2017-07-19 | MiniPumps, LLC | Electrolytic drug-delivery pump with adaptive control |
US20110066072A1 (en) * | 2009-09-11 | 2011-03-17 | Drexel University | Intracranial pressure sensor |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
CA2778678A1 (en) | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
ES2695907T3 (en) | 2009-11-17 | 2019-01-11 | Bard Inc C R | Overmolded access port that includes anchoring and identification features |
US8377034B2 (en) | 2009-12-04 | 2013-02-19 | Std Med, Inc. | Vascular access port |
US8177747B2 (en) | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
GB201002370D0 (en) * | 2010-02-12 | 2010-03-31 | Renishaw Ireland Ltd | Percutaneous drug delivery apparatus |
US8038650B2 (en) * | 2010-02-22 | 2011-10-18 | Microsert Ltd. | Slow release liquid drug delivery device |
AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
JP6294074B2 (en) | 2010-04-27 | 2018-03-14 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
CA2797393C (en) | 2010-04-29 | 2020-03-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
CN103096925A (en) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases |
CA2797978C (en) | 2010-05-03 | 2019-12-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
CN103096912A (en) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
CN102985103A (en) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
JP6396656B2 (en) | 2010-05-14 | 2018-09-26 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase |
US8962560B2 (en) | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
SI2600812T1 (en) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Apparatus to treat an eye |
EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
JP6046041B2 (en) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | Devices, systems, and methods for neuromodulation therapy evaluation and feedback |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
WO2012131583A2 (en) | 2011-03-27 | 2012-10-04 | Microsert Ltd. | Miniature implanted drug delivery devices and inserter systems for introducing such devices |
EA032666B1 (en) | 2011-06-14 | 2019-06-28 | Бикам Фармасьютикалз, Инк. | Opsin-binding ligands and methods of use thereof |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
SI2755600T1 (en) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Fluid exchange apparatus |
EP2768307B1 (en) | 2011-10-19 | 2020-03-18 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8685106B2 (en) | 2011-11-15 | 2014-04-01 | Abraham Lin | Method of a pharmaceutical delivery system for use within a joint replacement |
US9353063B2 (en) | 2011-11-30 | 2016-05-31 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
CA2862746A1 (en) | 2011-12-01 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9510777B2 (en) | 2012-03-08 | 2016-12-06 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring of neuromodulation using biomarkers |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US9707339B2 (en) | 2012-03-28 | 2017-07-18 | Angiodynamics, Inc. | High flow rate dual reservoir port system |
US9713704B2 (en) | 2012-03-29 | 2017-07-25 | Bradley D. Chartrand | Port reservoir cleaning system and method |
US8761717B1 (en) | 2012-08-07 | 2014-06-24 | Brian K. Buchheit | Safety feature to disable an electronic device when a wireless implantable medical device (IMD) is proximate |
GB201217606D0 (en) | 2012-10-02 | 2012-11-14 | Renishaw Plc | Neurosurgical device and method |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
US9205242B2 (en) | 2012-11-19 | 2015-12-08 | Angiodynamics, Inc. | Port septum with integral valve |
CN105142710A (en) | 2013-01-15 | 2015-12-09 | 科罗拉多州立大学董事会,公司实体 | Lacrimal system drug delivery device |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
EP4302736A3 (en) | 2013-03-28 | 2024-04-03 | ForSight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10369345B2 (en) | 2014-03-31 | 2019-08-06 | Versago Vascular Access, Inc. | Medical access port, systems and methods of use thereof |
US9764124B2 (en) | 2014-03-31 | 2017-09-19 | Versago Vascular Access, Inc. | Vascular access port |
EP3125985B1 (en) | 2014-04-03 | 2021-09-22 | Versago Vascular Access, Inc. | Devices and methods for installation and removal of a needle tip of a needle |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
AU2015364276B2 (en) | 2014-12-18 | 2020-04-30 | Versago Vascular Access, Inc. | Devices, systems and methods for removal and replacement of a catheter for an implanted access port |
JP6837971B2 (en) | 2014-12-18 | 2021-03-03 | ヴェルサゴ ヴァスキュラー アクセス インコーポレイテッド | Catheter patency system and method |
DE102015100224A1 (en) * | 2015-01-09 | 2016-07-14 | Aesculap Ag | Implantable drug delivery system |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
EP3322460B1 (en) | 2015-07-14 | 2022-09-07 | Versago Vascular Access, Inc. | Medical access ports and transfer devices |
KR101693350B1 (en) * | 2015-07-29 | 2017-01-06 | 이창윤 | Apparatus for ventricle drug injection |
CN108430405B (en) | 2015-11-20 | 2021-04-13 | 弗赛特影像4股份有限公司 | Porous structures for sustained release drug delivery devices |
CA3006042A1 (en) | 2015-11-23 | 2017-06-01 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
CA3024912A1 (en) | 2016-05-20 | 2017-11-23 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drug delivery device |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
US10744313B2 (en) | 2017-07-27 | 2020-08-18 | University Of Utah Research Foundation | Therapeutic delivery device |
WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
WO2019126306A1 (en) | 2017-12-21 | 2019-06-27 | Versago Vascular Access, Inc. | Medical access ports, transfer devices and methods of use thereof |
US10493233B1 (en) * | 2018-06-05 | 2019-12-03 | Duke University | Bi-directional access to tumors |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
CN110292705A (en) * | 2019-06-27 | 2019-10-01 | 山东科技大学 | A kind of remote control telocoele drug delivery system |
CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
RU2748544C1 (en) * | 2020-08-31 | 2021-05-26 | Общество С Ограниченной Ответственностью "Международный Центр Медицинских Исследований И Разработок" (Ооо "Мц Миир") | Method for targeted minimally invasive access for cell transplantation into bone regenerate |
EP3978065A1 (en) * | 2020-10-02 | 2022-04-06 | Heraeus Medical GmbH | Implant for local drug release |
CN112472976B (en) * | 2020-11-24 | 2022-04-01 | 昆明医科大学 | Double-balloon liquid storage device for treating brain glioma |
WO2024006844A1 (en) * | 2022-07-01 | 2024-01-04 | Genentech, Inc. | Implantable and refillable drug delivery reservoir system with porous metal frit for sustained intracerebroventricular delivery and methods of use |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3310051A (en) * | 1963-12-10 | 1967-03-21 | Rudolf R Schulte | Surgical reservoir for implantation beneath the skin |
CH557178A (en) * | 1972-08-10 | 1974-12-31 | Siemens Ag | DEVICE FOR DISPENSING DRUGS. |
GB1567889A (en) * | 1977-04-12 | 1980-05-21 | Nippon Kayaku Kk | Orally administrable anti-tumour compositions for enhancing absorption of antitumour agent into a gastrointestinal tomour site |
DE3138320A1 (en) * | 1981-09-25 | 1983-04-14 | Siemens AG, 1000 Berlin und 8000 München | INFUSION DEVICE PROVIDED FOR IMPLANTATION IN A LIVING BODY |
US4568331A (en) * | 1983-10-17 | 1986-02-04 | Marcus Fischer | Disposable medicine dispensing device |
US4681560A (en) * | 1984-03-16 | 1987-07-21 | Pudenz-Schulte Medical Research Corp. | Subcutaneous infusion reservoir and pump system |
US4588394A (en) * | 1984-03-16 | 1986-05-13 | Pudenz-Schulte Medical Research Corp. | Infusion reservoir and pump system |
US4816016A (en) * | 1984-03-16 | 1989-03-28 | Pudenz-Schulte Medical Research Corp. | Subcutaneous infusion reservoir and pump system |
US4761158A (en) * | 1984-03-16 | 1988-08-02 | Pudenz-Schulte Medical Research Corp. | Subcutaneous infusion reservoir and pump system |
US4687468A (en) * | 1984-10-01 | 1987-08-18 | Cook, Incorporated | Implantable insulin administration device |
IN165717B (en) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4871352A (en) * | 1987-12-07 | 1989-10-03 | Controlled Release Technologies, Inc. | Self-regulated therapeutic agent delivery system and method |
US5084015A (en) * | 1988-05-16 | 1992-01-28 | Terumo Kabushiki Kaisha | Catheter assembly of the hypodermic embedment type |
US4857053A (en) * | 1988-08-29 | 1989-08-15 | Dalton Michael J | Matrix septum |
US5011472A (en) * | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US4969871A (en) * | 1989-02-15 | 1990-11-13 | Alza Corporation | Intravenous system for delivering a beneficial agent |
US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5139023A (en) * | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
US5116493A (en) * | 1989-08-25 | 1992-05-26 | W. R. Grace & Co.-Conn. | Artificial pancreatic perfusion device with reseedable matrix |
US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
US5041107A (en) * | 1989-10-06 | 1991-08-20 | Cardiac Pacemakers, Inc. | Electrically controllable, non-occluding, body implantable drug delivery system |
SG48792A1 (en) * | 1991-06-28 | 1998-05-18 | Univ Brown Res Found | Renewable neural implant device and method |
-
1995
- 1995-11-09 AU AU41449/96A patent/AU708529B2/en not_active Expired
- 1995-11-09 CA CA002204789A patent/CA2204789C/en not_active Expired - Lifetime
- 1995-11-09 DK DK95939752T patent/DK0788351T3/en active
- 1995-11-09 ES ES95939752T patent/ES2191719T3/en not_active Expired - Lifetime
- 1995-11-09 DE DE69529572T patent/DE69529572T2/en not_active Expired - Lifetime
- 1995-11-09 EP EP95939752A patent/EP0788351B1/en not_active Expired - Lifetime
- 1995-11-09 WO PCT/US1995/014319 patent/WO1996014834A1/en active IP Right Grant
- 1995-11-09 AT AT95939752T patent/ATE232089T1/en active
- 1995-11-09 JP JP51614296A patent/JP3251294B2/en not_active Expired - Lifetime
- 1995-11-09 PT PT95939752T patent/PT788351E/en unknown
-
1997
- 1997-01-28 US US08/789,242 patent/US5836935A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE232089T1 (en) | 2003-02-15 |
DK0788351T3 (en) | 2003-05-26 |
ES2191719T3 (en) | 2003-09-16 |
JP3251294B2 (en) | 2002-01-28 |
PT788351E (en) | 2003-06-30 |
WO1996014834A1 (en) | 1996-05-23 |
AU708529B2 (en) | 1999-08-05 |
DE69529572T2 (en) | 2003-06-18 |
CA2204789A1 (en) | 1996-05-23 |
DE69529572D1 (en) | 2003-03-13 |
US5836935A (en) | 1998-11-17 |
JPH10508774A (en) | 1998-09-02 |
EP0788351A4 (en) | 1998-03-11 |
AU4144996A (en) | 1996-06-06 |
CA2204789C (en) | 2002-11-12 |
EP0788351A1 (en) | 1997-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0788351B1 (en) | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body | |
US6214370B1 (en) | Method and device for administering analgesics | |
US6436091B1 (en) | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent | |
Greenberg et al. | Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain | |
US6471688B1 (en) | Osmotic pump drug delivery systems and methods | |
US5997524A (en) | Catheter assembly for percutaneous access to subcutaneous port | |
US6632217B2 (en) | Implantable osmotic pump | |
US6464688B1 (en) | Osmotic pump delivery system with flexible drug compartment | |
AU7585301A (en) | Needle for intradermal delivery of substances having penetration limiting means | |
Brazenor | Long term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump | |
US20110046557A1 (en) | Microneedle drug delivery system including movable drug-containing capsule | |
US20040015154A1 (en) | Implantable devices with invasive and non-invasive reversible infusion rate adjustability | |
CN209771078U (en) | drug delivery device | |
US6616652B1 (en) | Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter | |
Dieckmann | Intraventricular Morphine Application by Means of Implanted Pump Systems in Paraneoplastic Pain Syndrome | |
Lazorthes et al. | Implantable Systems for Local Chronic Administration of Drug Applications in Neuropharmacology | |
Penn | Intrathecal delivery of medications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970516 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980126 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20001109 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69529572 Country of ref document: DE Date of ref document: 20030313 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030400328 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20030414 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2191719 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20031106 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20140926 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20141111 Year of fee payment: 20 Ref country code: LU Payment date: 20141119 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20141105 Year of fee payment: 20 Ref country code: CH Payment date: 20141112 Year of fee payment: 20 Ref country code: GB Payment date: 20141105 Year of fee payment: 20 Ref country code: SE Payment date: 20141111 Year of fee payment: 20 Ref country code: ES Payment date: 20141013 Year of fee payment: 20 Ref country code: FR Payment date: 20141110 Year of fee payment: 20 Ref country code: GR Payment date: 20141014 Year of fee payment: 20 Ref country code: IE Payment date: 20141110 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20141108 Year of fee payment: 20 Ref country code: AT Payment date: 20141027 Year of fee payment: 20 Ref country code: PT Payment date: 20141103 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20141113 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20141111 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69529572 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20151108 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20151109 Ref country code: DK Ref legal event code: EUP Effective date: 20151109 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20151108 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 232089 Country of ref document: AT Kind code of ref document: T Effective date: 20151109 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20151109 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20151108 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160226 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20151116 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MA Ref document number: 20030400328 Country of ref document: GR Effective date: 20151110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20151110 |